The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice
Open accessAbstract
The farnesoid X receptor (FXR) controls the synthesis and transport of bile acids (BAs). Mice lacking expression of FXR, designated Fxr-null, have elevated levels of serum and hepatic BAs and an increase in BA pool size. Surprisingly, at 12 months of age, male and female Fxr-null mice had a high incidence of degenerative hepatic lesions, altered cell foci and liver tumors including hepatocellular adenoma, carcinoma and hepatocholangiocellular carcinoma, the latter of which is rarely observed in mice. At 3 months, Fxr-null mice had increased expression of the proinflammatory cytokine IL-1beta mRNA and elevated beta-catenin and its target gene c-myc. They also had increased cell proliferation as revealed by increased PCNA mRNA and BrdU incorporation. These studies reveal a potential role for FXR and BAs in hepatocarcinogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ablation of Nr1h4 (hereafter referred to as Fxr) not only promotes cholestasis but also NAFLD, NASH and HCC in mice (Kim et al., 2007; Lu et al., 2000; Wang et al., 2008; Watanabe et al., 2004; Yang et al., 2007).”
From Circadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis (2016) · cites this paper as Kim et al., 2007
In the citing paper
“Fxr-deficient mice exhibit compromised intestinal integrity, with further deterioration after bile duct ligation20, and a high incidence of HCC140.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [140]
In the citing paper
“Nr1h4−/− mice also develop spontaneous hepatic inflammation and liver tumors (I. Kim et al., 2007; Yang et al., 2007).”
From Understanding the Holobiont: How Microbial Metabolites Affect Human Health and Shape the Immune System (2017) · cites this paper as I. Kim et al., 2007
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Self-citationKraupp, B. G., Ruttkay-Nedecký, B., Koudelka, H., Bukowska, K., Bursch, W., & Schulte‐Hermann, R. (1995) · Hepatology · doi:10.1002/hep.1840210534 · Cited by 1,223
Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice
Zhang, Y., Lee, F. Y., Barrera, G., Lee, H., Vales, C., Gonzalez, F. J., Willson, T. M., & Edwards, P. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506982103 · Cited by 974
Self-citationNuclear Receptor-Dependent Bile Acid Signaling Is Required for Normal Liver Regeneration
Huang, W., Ma, K., Zhang, J., Qatanani, M., Cuvillier, J., Liu, J., Dong, B., Huang, X., & Moore, D. D. (2006) · Science · doi:10.1126/science.1121435 · Cited by 645
Endocrine functions of bile acids
Houten, S. M., 渡辺, 光., & Auwerx, J. H. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601049 · Cited by 595
The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice
Cariou, B., van Harmelen, K., Durán-Sandoval, D., van Dijk, T. H., Grefhorst, A., Abdelkarim, M., Caron, S., Torpier, G., Fruchart, J., Gonzalez, F. J., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510258200 · Cited by 546
Self-citationToxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas
Faubion, W. A., Guicciardi, M. E., Miyoshi, H., Bronk, S. F., Roberts, P. J., Svingen, P. A., Kaufmann, S. H., & Gores, G. J. (1999) · Journal of Clinical Investigation · doi:10.1172/jci4765 · Cited by 539
Fiorucci, S., Antonelli, E., Rizzo, G., Renga, B., Mencarelli, A., Riccardi, L., Orlandi, S., Pellicciari, R., & Morelli, A. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.08.001 · Cited by 472
Activation of hepatic stellate cells - a key issue in liver fibrosis
Reeves, H. L. (2002) · Frontiers in bioscience · doi:10.2741/reeves · Cited by 421
Peraino, C., Fry, R. J., & Staffeldt, E. F. (1971) · PubMed · Cited by 410
Flagged first, then by citations
1 of the 38 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Haseman, 1999, Chapter 26, Neoplasm Incidences in B6C3F1 Mice: NTP Historical Data
Cited by
Sorted by citations
Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., & Staels, B. (2009) · Physiological Reviews · doi:10.1152/physrev.00010.2008 · Cited by 1,678
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Postler, T. S., & Ghosh, S. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.05.008 · Cited by 876
“Nr1h4 / mice also develop spontaneous hepatic inflammation and liver tumors (Kim et al., 2007; Yang et al., 2007).”
BackgroundBile acid receptors as targets for drug development
Schaap, F. G., Trauner, M., & Jansen, P. L. M. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.151 · Cited by 696
The gut microbiome and liver cancer: mechanisms and clinical translation
Yu, L.-X., & Schwabe, R. F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.72 · Cited by 634
Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine
Kim, I., Ahn, S.-H., Inagaki, T., Choi, M., Ito, S., Guo, G. L., Kliewer, S. A., & Gonzalez, F. J. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m700330-jlr200 · Cited by 589
Self-citationBile acids: Chemistry, physiology, and pathophysiology
Monte, M. J., Marı́n, J. J. G., Antelo, Á., & Tato, J. V. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.804 · Cited by 588
Fleishman, J. S., & Kumar, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01811-6 · Cited by 615
Circadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis
Kettner, N. M., Voicu, H., Finegold, M. J., Coarfa, C., Sreekumar, A., Putluri, N., Katchy, C. A., Lee, C., Moore, D. D., & Fu, L. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.007 · Cited by 508
“Ablation of Nr1h4 (hereafter referred to as Fxr) not only promotes cholestasis but also NAFLD, NASH and HCC in mice (Kim et al., 2007; Lu et al., 2000; Wang et al., 2008; Watanabe et al., 2004; Yang et al., 2007).”
BackgroundRole of bile acids and their receptors in gastrointestinal and hepatic pathophysiology
Fuchs, C. D., & Trauner, M. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00566-7 · Cited by 490
Molecular physiology of bile acid signaling in health, disease, and aging
Perino, A., Demagny, H., Velazquez-Villegas, L., & Schoonjans, K. (2021) · Physiological Reviews · doi:10.1152/physrev.00049.2019 · Cited by 481
Bile acids in glucose metabolism in health and disease
Shapiro, H., Kolodziejczyk, A. A., Halstuch, D., & Elinav, E. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20171965 · Cited by 481
The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer
Sun, L., Cai, J., & Gonzalez, F. J. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00404-2 · Cited by 459
Self-citationEndocrine fibroblast growth factors 15/19 and 21: from feast to famine
Potthoff, M. J., Kliewer, S. A., & Mangelsdorf, D. J. (2012) · Genes & Development · doi:10.1101/gad.184788.111 · Cited by 442
FXR: a metabolic regulator and cell protector
Wang, Y.-D., Chen, W.-D., Moore, D. D., & Huang, W. (2008) · Cell Research · doi:10.1038/cr.2008.289 · Cited by 389
FXR signaling in the enterohepatic system
Matsubara, T., Li, F., & Gonzalez, F. J. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.05.004 · Cited by 383
Self-citationBile acids as endogenous etiologic agents in gastrointestinal cancer
Bernstein, H., Bernstein, C., Payne, C. M., & Dvorak, K. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.3329 · Cited by 340
Bile Acid Metabolism and Signaling in Cholestasis, Inflammation, and Cancer
Li, T., & Apte, U. M. (2015) · Advances in pharmacology · doi:10.1016/bs.apha.2015.04.003 · Cited by 336
Deciphering the nuclear bile acid receptor FXR paradigm
Modica, S., Gadaleta, R. M., & Moschetta, A. (2010) · Nuclear Receptor Signaling · doi:10.1621/nrs.08005 · Cited by 304
Zhang, S., Wang, J., Liu, Q., & Harnish, D. C. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.03.025 · Cited by 290
Bile acids are nutrient signaling hormones
Zhou, H., & Hylemon, P. B. (2014) · Steroids · doi:10.1016/j.steroids.2014.04.016 · Cited by 285
Nuclear receptors and nonalcoholic fatty liver disease
Cave, M. C., Clair, H. B., Hardesty, J., Falkner, K. C., Feng, W., Clark, B. J., Sidey, J., Shi, H., Aqel, B. A., McClain, C. J., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2016.03.002 · Cited by 292
Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis
Xie, G., Wang, X., Huang, F., Zhao, A., Chen, W., Yan, J., Zhang, Y., Lei, S., Ge, K., Zheng, X., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30219 · Cited by 252
Nuclear Bile Acid Receptor FXR Protects against Intestinal Tumorigenesis
Modica, S., Murzilli, S., Salvatore, L., Schmidt, D. R., & Moschetta, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1791 · Cited by 240
Bile acid metabolism and signalling in liver disease
Fuchs, C. D., Simbrunner, B., Baumgartner, M., Campbell, C., Reiberger, T., & Trauner, M. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.09.032 · Cited by 265
Recent advances in the development of farnesoid X receptor agonists.
Ali, A. H., Carey, E. J., & Lindor, K. D. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2014.12.06 · Cited by 224
Maran, R. R. M., Thomas, A., Roth, M. E., Sheng, Z., Esterly, N., Pinson, D. M., Gao, X., Zhang, Y., Ganapathy, V., Gonzalez, F. J., et al. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.145409 · Cited by 221
Self-citationTargeting nuclear receptors for the treatment of fatty liver disease
Tanaka, N., Aoyama, T., Kimura, S., & Gonzalez, F. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.05.011 · Cited by 217
Self-citationBile acids and colon cancer: Solving the puzzle with nuclear receptors
Degirolamo, C., Modica, S., Palasciano, G., & Moschetta, A. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.05.010 · Cited by 214
FXR signaling in metabolic disease
Zhang, Y., & Edwards, P. A. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.11.015 · Cited by 212
Hippo signalling in the liver: role in development, regeneration and disease
Russell, J. O., & Camargo, F. D. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00571-w · Cited by 211
Bile Acids Activate YAP to Promote Liver Carcinogenesis
Anakk, S., Bhosale, M., Schmidt, V. A., Johnson, R. L., Finegold, M. J., & Moore, D. D. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.10.030 · Cited by 196
Molecular mechanisms involved in farnesol-induced apoptosis
Joo, J. H., & Jetten, A. M. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.05.015 · Cited by 203
Ma, J., Hong, Y., Zheng, N., Xie, G., Lyu, Y., Gu, Y., Xi, C., Chen, L., Wu, G., Li, Y., et al. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1763770 · Cited by 171
Mencarelli, A., Renga, B., Migliorati, M., Cipriani, S., Distrutti, E., Santucci, L., & Fiorucci, S. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901347 · Cited by 177
Sterol Regulation of Metabolism, Homeostasis, and Development
Wollam, J., & Antebi, A. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-081308-165917 · Cited by 172
Bile acids and signal transduction: Role in glucose homeostasis
Nguyen, A., & Bouscarel, B. E. (2008) · Cellular Signalling · doi:10.1016/j.cellsig.2008.06.014 · Cited by 167
Bile acids and their receptors
Martinot, E., Sèdes, L., Baptissart, M., Lobaccaro, J.-M., Caira, F., Beaudoin, C., & Volle, D. H. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.01.006 · Cited by 162
FXR in liver physiology: Multiple faces to regulate liver metabolism
Panzitt, K., & Wagner, M. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166133 · Cited by 170
Sheng, L., Jena, P. K., Liu, H., Kalanetra, K. M., Gonzalez, F. J., French, S. W., Krishnan, V. V., Mills, D. A., & Wan, Y. Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-01576-9 · Cited by 157
Self-citationAkwabi-Ameyaw, A., Bass, J. Y., Caldwell, R. D., Caravella, J. A., Chen, L., Creech, K. L., Deaton, D. N., Jones, S. A., Kaldor, I. W., Liu, Y., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.06.073 · Cited by 151
Promotion of liver regeneration/repair by farnesoid X receptor in both liver and intestine in mice
Zhang, L., Wang, Y.-D., Chen, W.-D., Wang, X., Lou, G., Liu, N., Lin, M., Forman, B. M., & Huang, W. (2012) · Hepatology · doi:10.1002/hep.25905 · Cited by 151
Nuclear receptors as therapeutic targets in cholestatic liver diseases
Zollner, G., & Trauner, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00030.x · Cited by 146
Wolfe, A. R., Thomas, A., Edwards, G., Jaseja, R., Guo, G. L., & Apte, U. M. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.179390 · Cited by 145
Bile acids and their receptors: modulators and therapeutic targets in liver inflammation
Bertolini, A., Fiorotto, R., & Strazzabosco, M. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00935-7 · Cited by 150
Abdollahi‐Roodsaz, S., Abramson, S. B., & Scher, J. U. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.68 · Cited by 142
Servitja, J., Pignatelli, M., Maestro, M. Á., Cardalda, C. A., Boj, S. F., Lozano, J. J., Blanco, E., Lafuente, A., McCarthy, M. I., Sumoy, L., et al. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01389-08 · Cited by 145
Bile acid receptors in non-alcoholic fatty liver disease
Li, Y., Jadhav, K. S., & Zhang, Y. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.08.015 · Cited by 140
Sheng, L., Jena, P. K., Hu, Y. C., Liu, H., Nagar, N., Kalanetra, K. M., French, S. W., French, S. W., Mills, D. A., & Wan, Y. Y. (2017) · The Journal of Pathology · doi:10.1002/path.4983 · Cited by 133
Liver carcinogenesis by FOS-dependent inflammation and cholesterol dysregulation
Bakiri, L., Hamacher, R., Graña‐Castro, O., Guío-Carrión, A., Campos‐Olivas, R., Martínez, L., Dienes, H. P., Thomsen, M. K., Hasenfuss, S. C., & Wagner, E. F. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20160935 · Cited by 135
Loss of FXR Protects against Diet-Induced Obesity and Accelerates Liver Carcinogenesis in ob/ob Mice
Zhang, Y., Ge, X., Heemstra, L. A., Chen, W., Xu, J., Smith, J. L., Ma, H., Kasim, N., Edwards, P. A., & Novak, C. M. (2012) · Molecular Endocrinology · doi:10.1210/me.2011-1157 · Cited by 128
Cholestatic liver (dys)function during sepsis and other critical illnesses
Jenniskens, M., Langouche, L., Vanwijngaerden, Y.-M., Mesotten, D., & Van den Berghe, G. (2016) · Intensive Care Medicine · doi:10.1007/s00134-015-4054-0 · Cited by 129
Vaquero, J., Monte, M. J., Domínguez, M., Muntané, J., & Marı́n, J. J. G. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.07.022 · Cited by 134
FXR Agonists as Therapeutic Agents for Non-alcoholic Fatty Liver Disease
Carr, R. M., & Reid, A. E. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0500-2 · Cited by 126
Degirolamo, C., Modica, S., Vacca, M., Di Tullio, G., Morgano, A., D'Orazio, A., Kannisto, K., Parini, P., & Moschetta, A. (2015) · Hepatology · doi:10.1002/hep.27274 · Cited by 121
TGR5: A Novel Target for Weight Maintenance and Glucose Metabolism
Chen, X., Lou, G., Meng, Z., & Huang, W. (2011) · Experimental Diabetes Research · doi:10.1155/2011/853501 · Cited by 125
The Role of FXR in Disorders of Bile Acid Homeostasis
Eloranta, J. J., & Kullak-Ublick, G. A. (2008) · Physiology · doi:10.1152/physiol.00020.2008 · Cited by 120
Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease
Jiao, T., Ma, Y., Guo, X., Ye, Y., & Xie, C. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00880-z · Cited by 122
Fatty liver diseases, bile acids, and FXR
Zhu, Y., Liu, H., Zhang, M., & Guo, G. L. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.07.008 · Cited by 122
Nuclear Receptors as New Perspective for the Management of Liver Diseases
Trauner, M., & Halilbasic, E. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.044 · Cited by 115
Farnesoid X receptor: A “homeostat” for hepatic nutrient metabolism
Massafra, V., & van Mil, S. W. C. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.10.003 · Cited by 115
Role of farnesoid X receptor and bile acids in alcoholic liver disease
Manley, S., & Ding, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2014.12.011 · Cited by 116
Jena, P. K., Sheng, L., Liu, H., Kalanetra, K. M., Mirsoian, A., Murphy, W. J., French, S. W., Krishnan, V. V., Mills, D. A., & Wan, Y. Y. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.04.019 · Cited by 110
Tissue-specific actions of FXR in metabolism and cancer
Gadaleta, R. M., Cariello, M., Sabbà, C., & Moschetta, A. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.08.005 · Cited by 112
Deletion of mouse FXR gene disturbs multiple neurotransmitter systems and alters neurobehavior
Huang, F., Wang, T., Lan, Y., Yang, L., Pan, W., Zhu, Y., Lv, B., Wei, Y., Shi, H., Wu, H., et al. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00070 · Cited by 109
Liu, N., Meng, Z., Lou, G., Zhou, W., Wang, X., Zhang, Y., Zhang, L., Liu, X., Yen, Y., Lai, L. L., et al. (2012) · Molecular Endocrinology · doi:10.1210/me.2011-1383 · Cited by 110
Nuclear bile acid signaling through the farnesoid X receptor
Mazuy, C., Helleboid‐Chapman, A., Staels, B., & Lefèbvre, P. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1805-y · Cited by 113
Su, H., Ma, C., Liu, J., Li, N., Gao, M., Huang, A., Wang, X., Huang, W., & Huang, X. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00439.2011 · Cited by 106
Gao, L., Lv, G., Li, R., Liu, W., Zong, C., Ye, F., Li, X., Yang, X. F., Jiang, J., Hou, X., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.04.009 · Cited by 101
de la Rosa, L. C., García‐Ruiz, C., Vallejo, C., Baulies, A., Núñez, S., Monte, M. J., Marı́n, J. J. G., Baila-Rueda, L., Cenarro, A., Civeira, F., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.01.028 · Cited by 101
Tissue-specific function of farnesoid X receptor in liver and intestine
Zhu, Y., Li, F., & Guo, G. L. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2010.12.018 · Cited by 103
Claudel, T., Zollner, G., Wagner, M., & Trauner, M. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.12.021 · Cited by 104
Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases
Halilbasic, E., Baghdasaryan, A., & Trauner, M. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.12.001 · Cited by 100
Borude, P. C., Edwards, G., Walesky, C. M., Li, F., Ma, X., Kong, B., Guo, G. L., & Apte, U. M. (2012) · Hepatology · doi:10.1002/hep.25918 · Cited by 99
Bile acids and colon cancer: Is FXR the solution of the conundrum?
Gadaleta, R. M., García‐Irigoyen, O., & Moschetta, A. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.04.002 · Cited by 98
Cariello, M., Piccinin, E., García‐Irigoyen, O., Sabbà, C., & Moschetta, A. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.09.019 · Cited by 102
Bile acids: From digestion to cancers
Baptissart, M., Vega, A., Maqdasy, S., Caira, F., Baron, S., Lobaccaro, J.-M. A., & Volle, D. H. (2013) · Biochimie · doi:10.1016/j.biochi.2012.06.022 · Cited by 97
FXR Isoforms Control Different Metabolic Functions in Liver Cells via Binding to Specific DNA Motifs
Pittol, J. M. R., Milona, A., Morris, I., Willemsen, E. C. L., van der Veen, S. W., Kalkhoven, E., & van Mil, S. W. C. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.07.036 · Cited by 102
Huang, X., Zhao, W., & Huang, W. (2014) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.117 · Cited by 98
Intestinal Farnesoid X Receptor Signaling Modulates Metabolic Disease
Gonzalez, F. J., Jiang, C., Xie, C., & Patterson, A. D. (2017) · Digestive Diseases · doi:10.1159/000450908 · Cited by 96
Self-citationBile Acid Receptors and Liver Cancer
Wang, X., Fu, X., Ness, C. V., Meng, Z., Ma, X., & Huang, W. (2012) · Current Pathobiology Reports · doi:10.1007/s40139-012-0003-6 · Cited by 92
Nuclear Receptor Control of Enterohepatic Circulation
Gonzalez, F. J. (2012) · Comprehensive physiology · doi:10.1002/cphy.c120007 · Cited by 105
Self-citationNuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity
Zollner, G., Wagner, M., & Trauner, M. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.03.005 · Cited by 91
Milona, A., Owen, B., van Mil, S. V., Dormann, D., Mataki, C., Boudjelal, M., Cairns, W., Schoonjans, K., Milligan, S., Parker, M., et al. (2010) · American Journal of Physiology - Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00336.2009 · Cited by 88
Nuclear receptors as therapeutic targets in liver disease: are we there yet?
Rudraiah, S., Zhang, X., & Wang, L. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103209 · Cited by 87
Recent advances on FXR-targeting therapeutics
Panzitt, K., Zollner, G., Marschall, H., & Wagner, M. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111678 · Cited by 88
The Role of Gut Microbiota in Some Liver Diseases: From an Immunological Perspective
Wang, L., Cao, Z.-M., Zhang, L., Li, J.-M., & Lv, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.923599 · Cited by 89
Yang, F., Hu, Y. C., Liu, H., & Wan, Y. Y. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.620369 · Cited by 85
Weaver, B. P., Zhang, Y., Hiscox, S., Guo, G. L., Apte, U. M., Taylor, K. M., Sheline, C. T., Wang, L., & Andrews, G. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013158 · Cited by 83
Zhang, Y., Gong, W., Dai, S.-S., Huang, G., Shen, X., Gao, M., Xu, Z., Zeng, Y., & He, F. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0473 · Cited by 85
Impact of bile acids on the growth of human cholangiocarcinoma via FXR
Dai, J., Wang, H., Shi, Y. H., Dong, Y., Zhang, Y., & Wang, J. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-41 · Cited by 85
Immunology of bile acids regulated receptors
Fiorucci, S., Marchianò, S., Urbani, G., Giorgio, C. D., Distrutti, E., Zampella, A., & Biagioli, M. (2024) · Progress in Lipid Research · doi:10.1016/j.plipres.2024.101291 · Cited by 88
Chen, Y., Song, X., Valanejad, L., Vasilenko, A., More, V. R., Qiu, X., Chen, W., Lai, Y., Slitt, A. L., Stoner, M. A., et al. (2012) · Hepatology · doi:10.1002/hep.26187 · Cited by 84
Attia, Y. M., Tawfiq, R. A., Ali, A. A., & Elmazar, M. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-12629-4 · Cited by 86
Bile acid receptors and nonalcoholic fatty liver disease
Yuan, L. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i28.2811 · Cited by 82
Metabolic Reprogramming of HCC: A New Microenvironment for Immune Responses
Foglia, B., Beltrà, M., Sutti, S., & Cannito, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087463 · Cited by 82
Deuschle, U., Schüler, J. B., Schulz, A., Schlüter, T., Kinzel, O. D., Abel, U. R., & Kremoser, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043044 · Cited by 81
Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression
Erice, O., Labiano, I., Arbelaiz, A., Santos‐Laso, Á., Muñoz-Garrido, P., Jiménez-Agüero, R., Olaizola, P., Caro‐Maldonado, A., Martín-Martín, N., Carracedo, A., et al. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.08.016 · Cited by 80
Familial intrahepatic cholestasis: New and wide perspectives
Vitale, G., Gitto, S., Vukotic, R., Raimondi, F., & Andreoné, P. (2019) · Digestive and Liver Disease · doi:10.1016/j.dld.2019.04.013 · Cited by 77
Suppression of interleukin-6-induced C-reactive protein expression by FXR agonists
Zhang, S., Liu, Q., Wang, J., & Harnish, D. C. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.12.117 · Cited by 77
Metadata
- Authors
- Kim, I., Morimura, K., Shah, Y., Yang, Q., Ward, J. M., & Gonzalez, F. J.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Gonzalez, Frank J.
- Venue
- Carcinogenesis
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-12-20
- Volume
- 28
- Issue
- 5
- Pages
- 940-946
- ISSN
- 0143-3334 (ISSN-L)
- 1460-2180
- PMC
- PMC1858639
- OpenAlex
- W2166661344
- Cited by
- 357
- References
- 38
- Citations by year
- 2026: 6 · 2025: 20 · 2024: 19 · 2023: 19 · 2022: 24 · 2021: 18 · 2020: 13 · 2019: 12 · 2018: 19 · 2017: 26 · 2016: 20 · 2015: 19 · 2014: 22 · 2013: 21 · 2012: 27
- FWCI
- 6.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Carcinogenesis (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (Z01BC005708)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Keywords
- farnesoid X receptor, hepatocarcinogenesis, bile acids, bile acid pool size, liver tumors, hepatocellular carcinoma, hepatocellular adenoma, IL-1β, β-catenin, c-Myc, cell proliferation, PCNA, BrdU incorporation
- MeSH terms
- Receptor, Farnesoid X-Activated, Animals, Bile Acids and Salts, Biological Transport, Cell Transformation, Neoplastic, DNA-Binding Proteins, Female, Carcinoma, Hepatocellular, Inflammation, Liver, Liver Neoplasms, Male, Mice, Mutant Strains, Transcription Factors, Gene Expression, Receptors, Cytoplasmic and Nuclear, Adenoma, Liver Cell, Cholangiocarcinoma, Cell Proliferation, beta Catenin, Mice, Interleukin-1beta
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
